Double immunotherapy attack shows promise against tough esophageal cancer
NCT ID NCT07290010
First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 23 times
Summary
This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy can shrink tumors and slow disease in people with advanced esophageal cancer that has come back or spread. About 25 adults whose cancer cannot be removed by surgery will receive the treatment for up to 24 months. The goal is to see how many patients respond and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei Medical University Fourth Hospital
RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.